Gorlin Syndrome - Pipeline Insight, 2019
This report can be delivered to the clients within 24 Hours
"Gorlin Syndrome - Pipeline Insight, 2019" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Gorlin Syndrome pipeline landscape is provided which includes the disease overview and Gorlin Syndrome treatment guidelines. The assessment part of the report embraces, in depth Gorlin Syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Gorlin Syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Gorlin Syndrome Understanding
Gorlin Syndrome also known as Nevoid basal cell carcinoma (NBCCS) or Gorlin-Goltz syndrome is an infrequent multisystemic disease that is inherited in an autosomal dominant way, and shows the high level of penetrance and variable expressiveness. Other distinguishing clinical features are seen in a majority of patients, and include keratocystic odontogenic tumors as well as dyskeratotic palmar and plantar pitting. Most people with Gorlin syndrome also develop noncancerous (benign) tumors of the jaw, called keratocystic odontogenic tumors. These tumors usually first appear during adolescence, and new tumors form until about age 30. Keratocystic odontogenic tumors rarely develop later in adulthood. If untreated, these tumors may cause painful facial swelling and tooth displacement. Other features of Gorlin syndrome include small depressions (pits) in the skin of the palms of the hands and soles of the feet; an unusually large head size (macrocephaly) with a prominent forehead; and skeletal abnormalities involving the spine, ribs, or skull. These signs and symptoms are typically apparent from birth or become evident in early childhood
Gorlin Syndrome Pipeline Development Activities
The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Gorlin Syndrome targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Gorlin Syndrome pipeline report covers 9+ companies. Some of the key players include Mayne Pharma (Itraconazole) and PellePharm (Patidegib) etc.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.
Gorlin Syndrome Analytical Perspective by DelveInsight
Scope of the report
"Gorlin Syndrome - Pipeline Insight, 2019" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Gorlin Syndrome pipeline landscape is provided which includes the disease overview and Gorlin Syndrome treatment guidelines. The assessment part of the report embraces, in depth Gorlin Syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Gorlin Syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Gorlin Syndrome Understanding
Gorlin Syndrome also known as Nevoid basal cell carcinoma (NBCCS) or Gorlin-Goltz syndrome is an infrequent multisystemic disease that is inherited in an autosomal dominant way, and shows the high level of penetrance and variable expressiveness. Other distinguishing clinical features are seen in a majority of patients, and include keratocystic odontogenic tumors as well as dyskeratotic palmar and plantar pitting. Most people with Gorlin syndrome also develop noncancerous (benign) tumors of the jaw, called keratocystic odontogenic tumors. These tumors usually first appear during adolescence, and new tumors form until about age 30. Keratocystic odontogenic tumors rarely develop later in adulthood. If untreated, these tumors may cause painful facial swelling and tooth displacement. Other features of Gorlin syndrome include small depressions (pits) in the skin of the palms of the hands and soles of the feet; an unusually large head size (macrocephaly) with a prominent forehead; and skeletal abnormalities involving the spine, ribs, or skull. These signs and symptoms are typically apparent from birth or become evident in early childhood
Gorlin Syndrome Pipeline Development Activities
The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Gorlin Syndrome targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Gorlin Syndrome pipeline report covers 9+ companies. Some of the key players include Mayne Pharma (Itraconazole) and PellePharm (Patidegib) etc.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.
Gorlin Syndrome Analytical Perspective by DelveInsight
- In-depth Gorlin Syndrome Commercial Assessment of products
- Gorlin Syndrome Clinical Assessment of products
Scope of the report
- The Gorlin Syndrome report provides an overview of therapeutic pipeline activity for Gorlin Syndrome across the complete product development cycle including all clinical and non-clinical stages
- It comprises of detailed profiles of Gorlin Syndrome therapeutic products with key coverage of developmental activities including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details
- Detailed Gorlin Syndrome Research and Development progress and trial details, results wherever available, are also included in the pipeline study
- Therapeutic assessment of the active pipeline products by development stage, product type, route of administration, molecule type, and MOA type
- Coverage of dormant and discontinued pipeline projects along with the reasons if available across Gorlin Syndrome
- Establish a comprehensive understanding of the current pipeline scenario across Gorlin Syndrome to formulate effective R&D strategies
- Assess challenges and opportunities that influence Gorlin Syndrome R&D
- Develop strategic initiatives by understanding the focus areas of leading companies.
- Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
- Get in detail information of each product with updated information on each project along with key milestones
- Devise Gorlin Syndrome in licensing and out licensing strategies by identifying prospective partners with progressing projects for Gorlin Syndrome to enhance and expand business potential and scope
- Our extensive domain knowledge on therapy areas support the clients in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs
1. REPORT INTRODUCTION
2. GORLIN SYNDROME (NEVOID BASAL CELL CARCINOMA (NBCCS) OR GORLIN-GOLTZ SYNDROME)
2.1. Gorlin Syndrome Disease Overview
2.2. Gorlin Syndrome History
2.3. Gorlin Syndrome Symptoms
2.4. Gorlin Syndrome Causes
2.5. Gorlin Syndrome Pathophysiology
2.6. Gorlin Syndrome Diagnosis
2.6.1. Diagnostic Guidelines
3. GORLIN SYNDROME CURRENT TREATMENT PATTERNS
3.1. Treatment Guidelines
4. GORLIN SYNDROME - DELVEINSIGHT’S ANALYTICAL PERSPECTIVE
4.1. In-depth Commercial Assessment
4.1.1. Gorlin Syndrome companies collaborations, Licensing, Acquisition –Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Gorlin Syndrome Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Gorlin Syndrome Acquisition Analysis
4.2. Clinical Assessment of Pipeline Drugs
4.2.1. Assessment by Phase of Development
4.2.2. Assessment by Product Type (Mono / Combination)
4.2.2.1. Assessment by Stage and Product Type
4.2.3. Assessment by Route of Administration
4.2.3.1. Assessment by Stage and Route of Administration
4.2.4. Assessment by Molecule Type
4.2.4.1. Assessment by Stage and Molecule Type
4.2.5. Assessment by MOA
4.2.5.1. Assessment by Stage and MOA
5. GORLIN SYNDROME PIPELINE THERAPEUTICS
5.1. Late Stage Products (Phase-III)
5.1.1. Comparative Analysis
5.2. Mid Stage Products (Phase-II)
5.2.1. Comparative Analysis
5.3. Early Stage Products (Phase-I)
5.3.1. Comparative Analysis
5.4. Pre-clinical and Discovery Stage Products
5.4.1. Comparative Analysis
5.5. Inactive Products
6. GORLIN SYNDROME -PRODUCTS ANALYSIS
6.1. Product Profiles
6.1.1. Itraconazole- Mayne Pharma
6.1.1.1. Product Description
6.1.1.1.1. Product Overview
6.1.1.1.2. Mechanism of Action
6.1.1.2. Research and Development
6.1.1.2.1. Clinical Studies
6.1.1.2.1.1. Detailed Study Description
6.1.1.2.1.2. Study Results
6.1.1.2.1.3. Clinical Trials: Tabular View
6.1.1.3. Product Development Activities
6.1.1.3.1. Tabulated Product Summary
6.1.1.3.1.1. General Description Table
6.1.2. Patidegib- PellePharm
6.1.2.1. Product Description
6.1.2.1.1. Product Overview
6.1.2.1.2. Mechanism of Action
6.1.2.2. Research and Development
6.1.2.2.1. Clinical Studies
6.1.2.2.1.1. Detailed Study Description
6.1.2.2.1.2. Study Results
6.1.2.2.1.3. Clinical Trials: Tabular View
6.1.2.3. Product Development Activities
6.1.2.3.1. Tabulated Product Summary
6.1.2.3.1.1. General Description Table
To be continued in the report…………………………
7. RECENT TECHNOLOGIES
8. GORLIN SYNDROME KEY COMPANIES
8.1. PellePharm
8.2. QLT Inc.
8.3. Mayne Pharma
8.4. DUSA Pharmaceuticals
8.5. Ascend Biopharmaceuticals Ltd
8.6. Novartis Pharmaceuticals
9. GORLIN SYNDROME KEY PRODUCTS
9.1. Patidegib
9.2. verteporfin PDT
9.3. SUBA-Itraconazole
9.4. Levulan
9.5. ASN-002
9.6. Buparlisib
10. DORMANT AND DISCONTINUED PRODUCTS
10.1. Dormant Products
10.1.1. Reasons for being dormant
10.2. Discontinued Products
10.2.1. Reasons for the discontinuation
11. GORLIN SYNDROME - UNMET NEEDS
12. GORLIN SYNDROME - FUTURE PERSPECTIVES
13. APPENDIX
14. REPORT METHODOLOGY
14.1. Secondary Research
14.2. Expert Panel Validation
2. GORLIN SYNDROME (NEVOID BASAL CELL CARCINOMA (NBCCS) OR GORLIN-GOLTZ SYNDROME)
2.1. Gorlin Syndrome Disease Overview
2.2. Gorlin Syndrome History
2.3. Gorlin Syndrome Symptoms
2.4. Gorlin Syndrome Causes
2.5. Gorlin Syndrome Pathophysiology
2.6. Gorlin Syndrome Diagnosis
2.6.1. Diagnostic Guidelines
3. GORLIN SYNDROME CURRENT TREATMENT PATTERNS
3.1. Treatment Guidelines
4. GORLIN SYNDROME - DELVEINSIGHT’S ANALYTICAL PERSPECTIVE
4.1. In-depth Commercial Assessment
4.1.1. Gorlin Syndrome companies collaborations, Licensing, Acquisition –Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Gorlin Syndrome Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Gorlin Syndrome Acquisition Analysis
4.2. Clinical Assessment of Pipeline Drugs
4.2.1. Assessment by Phase of Development
4.2.2. Assessment by Product Type (Mono / Combination)
4.2.2.1. Assessment by Stage and Product Type
4.2.3. Assessment by Route of Administration
4.2.3.1. Assessment by Stage and Route of Administration
4.2.4. Assessment by Molecule Type
4.2.4.1. Assessment by Stage and Molecule Type
4.2.5. Assessment by MOA
4.2.5.1. Assessment by Stage and MOA
5. GORLIN SYNDROME PIPELINE THERAPEUTICS
5.1. Late Stage Products (Phase-III)
5.1.1. Comparative Analysis
5.2. Mid Stage Products (Phase-II)
5.2.1. Comparative Analysis
5.3. Early Stage Products (Phase-I)
5.3.1. Comparative Analysis
5.4. Pre-clinical and Discovery Stage Products
5.4.1. Comparative Analysis
5.5. Inactive Products
6. GORLIN SYNDROME -PRODUCTS ANALYSIS
6.1. Product Profiles
6.1.1. Itraconazole- Mayne Pharma
6.1.1.1. Product Description
6.1.1.1.1. Product Overview
6.1.1.1.2. Mechanism of Action
6.1.1.2. Research and Development
6.1.1.2.1. Clinical Studies
6.1.1.2.1.1. Detailed Study Description
6.1.1.2.1.2. Study Results
6.1.1.2.1.3. Clinical Trials: Tabular View
6.1.1.3. Product Development Activities
6.1.1.3.1. Tabulated Product Summary
6.1.1.3.1.1. General Description Table
6.1.2. Patidegib- PellePharm
6.1.2.1. Product Description
6.1.2.1.1. Product Overview
6.1.2.1.2. Mechanism of Action
6.1.2.2. Research and Development
6.1.2.2.1. Clinical Studies
6.1.2.2.1.1. Detailed Study Description
6.1.2.2.1.2. Study Results
6.1.2.2.1.3. Clinical Trials: Tabular View
6.1.2.3. Product Development Activities
6.1.2.3.1. Tabulated Product Summary
6.1.2.3.1.1. General Description Table
To be continued in the report…………………………
7. RECENT TECHNOLOGIES
8. GORLIN SYNDROME KEY COMPANIES
8.1. PellePharm
8.2. QLT Inc.
8.3. Mayne Pharma
8.4. DUSA Pharmaceuticals
8.5. Ascend Biopharmaceuticals Ltd
8.6. Novartis Pharmaceuticals
9. GORLIN SYNDROME KEY PRODUCTS
9.1. Patidegib
9.2. verteporfin PDT
9.3. SUBA-Itraconazole
9.4. Levulan
9.5. ASN-002
9.6. Buparlisib
10. DORMANT AND DISCONTINUED PRODUCTS
10.1. Dormant Products
10.1.1. Reasons for being dormant
10.2. Discontinued Products
10.2.1. Reasons for the discontinuation
11. GORLIN SYNDROME - UNMET NEEDS
12. GORLIN SYNDROME - FUTURE PERSPECTIVES
13. APPENDIX
14. REPORT METHODOLOGY
14.1. Secondary Research
14.2. Expert Panel Validation
LIST OF TABLES
Table 1. Gorlin Syndrome Diagnostic Guidelines
Table 2. Treatment Guidelines
Table 3. Assessment Summary
Table 4. Company-Company Collaborations (Licensing / Partnering) Analysis
Table 5. Gorlin Syndrome Acquisition Analysis
Table 6. Assessment by Phase of Development
Table 7. Assessment by Product Type (Mono / Combination)
Table 8. Assessment by Stage and Product Type
Table 9. Assessment by Route of Administration
Table 10. Assessment by Stage and Route of Administration
Table 11. Assessment by Molecule Type
Table 12. Assessment by Stage and Molecule Type
Table 13. Assessment by MOA
Table 14. Assessment by Stage and MOA
Table 15. Late Stage Products (Phase-III)
Table 16. Mid Stage Products (Phase-II)
Table 17. Early Stage Products (Phase-I)
Table 18. Pre-clinical and Discovery Stage Products
Table 19. Inactive Products
Table 20. Dormant Products
Table 21. Discontinued Products
Table 1. Gorlin Syndrome Diagnostic Guidelines
Table 2. Treatment Guidelines
Table 3. Assessment Summary
Table 4. Company-Company Collaborations (Licensing / Partnering) Analysis
Table 5. Gorlin Syndrome Acquisition Analysis
Table 6. Assessment by Phase of Development
Table 7. Assessment by Product Type (Mono / Combination)
Table 8. Assessment by Stage and Product Type
Table 9. Assessment by Route of Administration
Table 10. Assessment by Stage and Route of Administration
Table 11. Assessment by Molecule Type
Table 12. Assessment by Stage and Molecule Type
Table 13. Assessment by MOA
Table 14. Assessment by Stage and MOA
Table 15. Late Stage Products (Phase-III)
Table 16. Mid Stage Products (Phase-II)
Table 17. Early Stage Products (Phase-I)
Table 18. Pre-clinical and Discovery Stage Products
Table 19. Inactive Products
Table 20. Dormant Products
Table 21. Discontinued Products
LIST OF FIGURES
Figure 1. Disease Overview
Figure 2. History
Figure 3. Symptoms
Figure 4. Causes
Figure 5. Pathophysiology
Figure 6. Diagnostic Guidelines
Figure 7. Treatment Guidelines
Figure 8. Gorlin Syndrome companies collaborations, Licensing, Acquisition –Deal Value Trends
Figure 9. Company-Company Collaborations (Licensing / Partnering) Analysis
Figure 10. Gorlin Syndrome Acquisition Analysis
Figure 11. Assessment by Phase of Development
Figure 12. Assessment by Product Type (Mono / Combination)
Figure 13. Assessment by Stage and Product Type
Figure 14. Assessment by Route of Administration
Figure 15. Assessment by Stage and Route of Administration
Figure 16. Assessment by Molecule Type
Figure 17. Assessment by Stage and Molecule Type
Figure 18. Assessment by MOA
Figure 19. Assessment by Stage and MOA
Figure 20. Late Stage Products (Phase-III)
Figure 21. Mid Stage Products (Phase-II)
Figure 22. Early Stage Products (Phase-I)
Figure 23. Pre-clinical and Discovery Stage Products
Figure 24. Inactive Products
Figure 25. Dormant Products
Figure 26. Discontinued Products
Figure 27. Unmet Needs
KEY COMPANIES
Sun Pharmaceutical Industries
Roche
PellePharm
Pinnacle Biologics
QLT Inc.
HedgePath Pharmaceuticals, Inc.
DUSA Pharmaceuticals
Ascend Biopharmaceuticals Ltd
Novartis Pharmaceuticals
Figure 1. Disease Overview
Figure 2. History
Figure 3. Symptoms
Figure 4. Causes
Figure 5. Pathophysiology
Figure 6. Diagnostic Guidelines
Figure 7. Treatment Guidelines
Figure 8. Gorlin Syndrome companies collaborations, Licensing, Acquisition –Deal Value Trends
Figure 9. Company-Company Collaborations (Licensing / Partnering) Analysis
Figure 10. Gorlin Syndrome Acquisition Analysis
Figure 11. Assessment by Phase of Development
Figure 12. Assessment by Product Type (Mono / Combination)
Figure 13. Assessment by Stage and Product Type
Figure 14. Assessment by Route of Administration
Figure 15. Assessment by Stage and Route of Administration
Figure 16. Assessment by Molecule Type
Figure 17. Assessment by Stage and Molecule Type
Figure 18. Assessment by MOA
Figure 19. Assessment by Stage and MOA
Figure 20. Late Stage Products (Phase-III)
Figure 21. Mid Stage Products (Phase-II)
Figure 22. Early Stage Products (Phase-I)
Figure 23. Pre-clinical and Discovery Stage Products
Figure 24. Inactive Products
Figure 25. Dormant Products
Figure 26. Discontinued Products
Figure 27. Unmet Needs
KEY COMPANIES
Sun Pharmaceutical Industries
Roche
PellePharm
Pinnacle Biologics
QLT Inc.
HedgePath Pharmaceuticals, Inc.
DUSA Pharmaceuticals
Ascend Biopharmaceuticals Ltd
Novartis Pharmaceuticals
